Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Samarth Kulkarni net worth and biography

Samarth Kulkarni Biography and Net Worth

CEO of CRISPR Therapeutics

Dr. Samarth Kulkarni has served as our Chief Executive Officer since 2017. He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then was appointed to President and Chief Business Officer before becoming CEO. Prior to joining our company, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, where he focused on strategy and operations, and led initiatives in areas such as personalized medicine and immunotherapy. Previously, Sam served as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer. Sam currently serves on the Board of Directors of two precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics. He also serves on the Board of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO). He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research on the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.

What is Samarth Kulkarni's net worth?: The estimated net worth of Samarth Kulkarni is at least $7.27 million as of December 2nd, 2024. Dr. Kulkarni owns 181,540 shares of CRISPR Therapeutics stock worth more than $7,265,231 as of December 29th. This net worth estimate does not reflect any other investments that Dr. Kulkarni may own. Additionally, Dr. Kulkarni receives a salary of $1,180,000.00 as CEO at CRISPR Therapeutics. Learn More about Samarth Kulkarni's net worth.
How old is Samarth Kulkarni?: Dr. Kulkarni is currently 43 years old. There are 4 older executives and no younger executives at CRISPR Therapeutics. Learn More on Samarth Kulkarni's age.
What is Samarth Kulkarni's salary?: As the CEO of CRISPR Therapeutics AG, Dr. Kulkarni earns $1,180,000.00 per year. Learn More on Samarth Kulkarni's salary.
How do I contact Samarth Kulkarni?: The corporate mailing address for Dr. Kulkarni and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Samarth Kulkarni's contact information.
Has Samarth Kulkarni been buying or selling shares of CRISPR Therapeutics?: Over the course of the past ninety days, Samarth Kulkarni has sold $2,693,780.04 in CRISPR Therapeutics stock. Most recently, Samarth Kulkarni sold 15,000 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a transaction totalling $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares of the company's stock, valued at $10,002,854. Learn More on Samarth Kulkarni's trading history.
Who are CRISPR Therapeutics' active insiders?: CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 207,740 shares worth more than $13,340,812.47. The most recent insider tranaction occured on December, 2nd when CEO Samarth Kulkarni sold 15,000 shares worth more than $826,500.00. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.
Information on this page was last updated on 12/2/2024.

Samarth Kulkarni Insider Trading History at CRISPR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/2/2024	Sell	15,000	$55.10	$826,500.00	181,540
11/11/2024	Sell	30,000	$55.62	$1,668,600.00	196,540
10/14/2024	Sell	4,293	$46.28	$198,680.04	226,540
4/15/2024	Sell	19,582	$59.91	$1,173,157.62	208,122
3/15/2024	Sell	20,000	$72.48	$1,449,600.00	208,122
3/11/2024	Sell	9,802	$78.26	$767,104.52	203,705
2/20/2024	Sell	6,370	$79.67	$507,497.90	194,257
2/15/2024	Sell	20,000	$80.36	$1,607,200.00	187,377
1/29/2024	Sell	50,000	$60.51	$3,025,500.00	187,377
1/16/2024	Sell	20,000	$62.50	$1,250,000.00	187,377
5/30/2023	Sell	25,000	$64.88	$1,622,000.00	387,377
4/25/2023	Sell	25,000	$50.67	$1,266,750.00	387,377
3/29/2023	Sell	25,000	$44.46	$1,111,500.00	387,377
2/27/2023	Sell	25,000	$48.25	$1,206,250.00	375,988
1/27/2023	Sell	25,000	$51.47	$1,286,750.00	369,111
12/28/2022	Sell	25,000	$40.93	$1,023,250.00	369,111
11/28/2022	Sell	25,000	$54.03	$1,350,750.00	290,279
10/26/2022	Sell	25,000	$54.81	$1,370,250.00	290,279
9/28/2022	Sell	25,000	$64.61	$1,615,250.00	290,279
8/29/2022	Sell	25,000	$66.84	$1,671,000.00	290,279
7/27/2022	Sell	25,000	$75.91	$1,897,750.00	290,279
6/29/2022	Sell	25,000	$61.59	$1,539,750.00	290,279
8/4/2021	Sell	1,500	$125.02	$187,530.00	189,219
6/15/2021	Sell	30,000	$126.43	$3,792,900.00	217,719
1/15/2021	Sell	20,000	$213.67	$4,273,400.00	202,989
12/10/2020	Sell	20,000	$142.29	$2,845,800.00	189,189
6/1/2020	Sell	17,275	$64.68	$1,117,347.00	188,801
5/20/2020	Sell	10,693	$65.28	$698,039.04	175,833
6/17/2019	Sell	20,000	$46.00	$920,000.00	185,801
4/29/2019	Sell	20,000	$42.03	$840,600.00	186,542
6/1/2018	Sell	15,000	$69.36	$1,040,400.00	163,560
8/30/2017	Sell	27,154	$20.08	$545,252.32	110,893
4/27/2017	Sell	5,481	$16.76	$91,861.56	137,322
4/25/2017	Sell	11,615	$16.78	$194,899.70	137,047

Samarth Kulkarni Buying and Selling Activity at CRISPR Therapeutics

CRISPR Therapeutics Company Overview

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Today's Range

Now: $38.69

$38.20

$39.67

50 Day Range

MA: $47.68

$40.02

$55.15

2 Week Range

Now: $38.69

$38.20

$91.10

Volume

1,090,128 shs

Average Volume

1,516,825 shs

Market Capitalization

$3.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Missed Nvidia? Buy Elon Musk’s “Silent Partner”

From Brownstone Research | Ad

So please click here to see the details because a lot of people could get rich.

Samarth Kulkarni Biography and Net Worth

What is Samarth Kulkarni's net worth?

How old is Samarth Kulkarni?

What is Samarth Kulkarni's salary?

How do I contact Samarth Kulkarni?

Has Samarth Kulkarni been buying or selling shares of CRISPR Therapeutics?

Who are CRISPR Therapeutics' active insiders?

Are insiders buying or selling shares of CRISPR Therapeutics?